Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Topotecan. Found 13 abstracts

Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.   PMCID: PMC 2668552
Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical Cancer Research. 2004 Dec;10(23):8048-58.
Treat J. Weekly topotecan in the management of lung cancer. Lung Cancer. 2003 Aug;41 Suppl 4:S27-31.
Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin Oncol. 2002 Feb;29(1 Suppl 1):20-31.
Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ, Zhou BB. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res. 2002 Mar 15;62(6):1797-801.
Hudes G. Boosting bioavailability of topotecan: what do we gain?. J Clin Oncol. 2002 Jul;20(13):2918-9.
Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2001 Jan;11 Suppl 1:42-51.
Huang CH, Treat J. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors. Oncology. 2001 Jan;61 Suppl 1:14-24.
Murphy BA, Leong T, Burkey B, Langer C, Forastiere A. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). Am J Clin Oncol. 2001 Feb;24(1):64-6.
Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RF. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol. 2001 Feb 15;19(4):1183-94.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol. 2000 Jun;18(12):2459-67.
Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist. 1999 Jan;4(2):87-94.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Topotecan

Topotecan drug therapy Human Female therapeutic use Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols administration & dosage Male Carboplatin Ovarian Neoplasms Paclitaxel US Gov't Support-PHS pathology Clinical Trials Middle Age Drug Administration Schedule Aged Type I DNA Topoisomerases pharmacokinetics Non-US Gov't Support Disease-Free Survival Deoxycytidine Adult drug effects antagonists & inhibitors physiology Lung Neoplasms Squamous Cell Carcinoma Enzyme Inhibitors Non-Small-Cell Lung Carcinoma metabolism Neoplasms Intravenous Infusions Local Neoplasm Recurrence Survival Analysis Oral Administration therapy Prognosis pharmacology analogs & derivatives adverse effects Neoplasm Drug Resistance Small Cell Carcinoma Doxorubicin Brain Neoplasms Ubiquitin Randomized Controlled Trials Molecular Sequence Data Head and Neck Neoplasms Cell Survival me [Metabolism] Cell Cycle Proteins 0 (Sesquiterpenes) effects ATP-Binding Cassette Transporters ad [Administration & Dosage] Heterologous Transplantation Cultured Tumor Cells Predictive Value of Tests derivatives Liposomes Ligases Neutropenia Biological Response Modifiers tu [Therapeutic Use] administration & Stomatitis 129298-91-5 (O-(chloroacetylcarbamoyl)fumagillol) Cell Cycle Isoquinolines diagnosis 0 (Antineoplastic Combined Chemotherapy Protocols) analogs & 85622-93-1 (temozolomide) chemically induced enzymology Multiple Drug Resistance Phase III Clinical Trials pk Neoplasm Proteins drug Vascular Endothelial Growth Factor A 123948-87-8 (Topotecan) Intestinal Absorption Phase I Clinical Trials Middle Aged 0 (Vascular Endothelial Growth Factor A) Rats Theoretical Models Cisplatin secondary aa [Analogs & Derivatives] 4342-03-4 (Dacarbazine) Breast Neoplasms Peritoneal Neoplasms Inbred F344 Rats Etoposide Recurrence Kidney Neoplasm Staging Carcinoma human) 0 (vascular endothelial growth factor A P-Glycoprotein mortality [Pharmacokinetics] Tertiary Protein Structure Nude Rats use Salvage Therapy Dacarbazine Hematopoietic Stem Cell Transplantation Hospitalization dosage DNA Damage Body Constitution Biological Models Time Factors Sesquiterpenes DNA Adducts genetics Polyethylene Glycols Computer Simulation Treatment Outcome 41575-94-4 (Carboplatin) Cervix Neoplasms dt [Drug Therapy] Biological Availability Acridines Stress therapeutic Neoplasm Metastasis adverse Amino Acid Sequence Mitosis
Last updated on Wednesday, February 05, 2020